Feasibility and applicability of diffusion-weighted and dynamic contrast-enhanced magnetic resonance imaging in routine assessments of children with high-grade gliomas
Corresponding Author
Fernando Carceller
Paediatric & Adolescent Drug Development Team, Children & Young People's Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom
Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom
Fernando Carceller and Neil P. Jerome contributed equally to this manuscript.
Correspondence
Fernando Carceller, Children and Young People's Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom.
Email: [email protected]
Search for more papers by this authorNeil P. Jerome
Cancer Research UK Cancer Imaging Centre, The Institute of Cancer Research, London, United Kingdom
Fernando Carceller and Neil P. Jerome contributed equally to this manuscript.
Search for more papers by this authorKeiko Miyazaki
Cancer Research UK Cancer Imaging Centre, The Institute of Cancer Research, London, United Kingdom
Search for more papers by this authorDavid J. Collins
Cancer Research UK Cancer Imaging Centre, The Institute of Cancer Research, London, United Kingdom
Search for more papers by this authorMatthew R. Orton
Cancer Research UK Cancer Imaging Centre, The Institute of Cancer Research, London, United Kingdom
Search for more papers by this authorJames A. d'Arcy
Cancer Research UK Cancer Imaging Centre, The Institute of Cancer Research, London, United Kingdom
Search for more papers by this authorToni Wallace
Radiology Department, The Royal Marsden NHS Foundation Trust, London, United Kingdom
Search for more papers by this authorLucas Moreno
Paediatric & Adolescent Drug Development Team, Children & Young People's Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom
Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom
Clinical Trials Unit, Paediatric Oncology Department, Hospital Niño Jesús, Madrid, Spain
Search for more papers by this authorAndrew D. J. Pearson
Paediatric & Adolescent Drug Development Team, Children & Young People's Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom
Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom
Retired.
Search for more papers by this authorStergios Zacharoulis
Paediatric & Adolescent Drug Development Team, Children & Young People's Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom
Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom
Search for more papers by this authorMartin O. Leach
Cancer Research UK Cancer Imaging Centre, The Institute of Cancer Research, London, United Kingdom
Search for more papers by this authorLynley V. Marshall
Paediatric & Adolescent Drug Development Team, Children & Young People's Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom
Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom
Search for more papers by this authorDow-Mu Koh
Radiology Department, The Royal Marsden NHS Foundation Trust, London, United Kingdom
Search for more papers by this authorCorresponding Author
Fernando Carceller
Paediatric & Adolescent Drug Development Team, Children & Young People's Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom
Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom
Fernando Carceller and Neil P. Jerome contributed equally to this manuscript.
Correspondence
Fernando Carceller, Children and Young People's Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom.
Email: [email protected]
Search for more papers by this authorNeil P. Jerome
Cancer Research UK Cancer Imaging Centre, The Institute of Cancer Research, London, United Kingdom
Fernando Carceller and Neil P. Jerome contributed equally to this manuscript.
Search for more papers by this authorKeiko Miyazaki
Cancer Research UK Cancer Imaging Centre, The Institute of Cancer Research, London, United Kingdom
Search for more papers by this authorDavid J. Collins
Cancer Research UK Cancer Imaging Centre, The Institute of Cancer Research, London, United Kingdom
Search for more papers by this authorMatthew R. Orton
Cancer Research UK Cancer Imaging Centre, The Institute of Cancer Research, London, United Kingdom
Search for more papers by this authorJames A. d'Arcy
Cancer Research UK Cancer Imaging Centre, The Institute of Cancer Research, London, United Kingdom
Search for more papers by this authorToni Wallace
Radiology Department, The Royal Marsden NHS Foundation Trust, London, United Kingdom
Search for more papers by this authorLucas Moreno
Paediatric & Adolescent Drug Development Team, Children & Young People's Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom
Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom
Clinical Trials Unit, Paediatric Oncology Department, Hospital Niño Jesús, Madrid, Spain
Search for more papers by this authorAndrew D. J. Pearson
Paediatric & Adolescent Drug Development Team, Children & Young People's Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom
Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom
Retired.
Search for more papers by this authorStergios Zacharoulis
Paediatric & Adolescent Drug Development Team, Children & Young People's Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom
Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom
Search for more papers by this authorMartin O. Leach
Cancer Research UK Cancer Imaging Centre, The Institute of Cancer Research, London, United Kingdom
Search for more papers by this authorLynley V. Marshall
Paediatric & Adolescent Drug Development Team, Children & Young People's Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom
Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom
Search for more papers by this authorDow-Mu Koh
Radiology Department, The Royal Marsden NHS Foundation Trust, London, United Kingdom
Search for more papers by this authorAbstract
Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) have been used as imaging biomarkers in adults with high-grade gliomas (HGGs). We incorporated free-breathing DW-MRI and DCE-MRI, at a single time point, in the routine follow-up of five children (median age 9 years, range 8–15) with histologically confirmed HGG within a prospective imaging study. It was feasible to incorporate DW-MRI and DCE-MRI in routine assessments of children with HGG. DW and DCE parameters were repeatable in paediatric HGG. Higher median ADC100-1000 significantly correlated with longer survival in our sample.
Supporting Information
Disclaimer: Supplementary materials have been peer-reviewed but not copyedited.
| Filename | Description |
|---|---|
| pbc26216-sup-0001-TableS1.docx18.7 KB | SUPPLEMENTARY TABLE S1 Patient demographics |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Fangusaro J. Pediatric high grade glioma: A review and update on tumor clinical characteristics and biology. Front Oncol. 2012; 2: 105.
- 2Fowkes LA, Koh D-M, Collins DJ, et al. Childhood extracranial neoplasms: The role of imaging in drug development and clinical trials. Pediatr Radiol. 2015; 45(11): 1600–1615.
- 3Jain R, Scarpace LM, Ellika S, et al. Imaging response criteria for recurrent gliomas treated with bevacizumab: Role of diffusion weighted imaging as an imaging biomarker. J Neurooncol. 2010; 96(3): 423–431.
- 4Pope WB, Qiao XJ, Kim HJ, et al. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: A multi-center study. J Neurooncol. 2012; 108(3): 491–498.
- 5Nguyen TB, Cron GO, Mercier JF, et al. Preoperative prognostic value of dynamic contrast-enhanced MRI-derived contrast transfer coefficient and plasma volume in patients with cerebral gliomas. AJNR Am J Neuroradiol. 2015; 36(1): 63–69.
- 6Rau MK, Braun C, Skardelly M, et al. Prognostic value of blood flow estimated by arterial spin labeling and dynamic susceptibility contrast-enhanced MR imaging in high-grade gliomas. J Neurooncol. 2014; 120(3): 557–566.
- 7Qu J, Qin L, Cheng S, et al. Residual low ADC and high FA at the resection margin correlate with poor chemoradiation response and overall survival in high-grade glioma patients. Eur J Radiol. 2016; 85(3): 657–664.
- 8Leach MO, Brindle KM, Evelhoch JL, et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: Issues and recommendations. Br J Cancer. 2005; 92(9): 1599–1610.
- 9Miyazaki K, Jerome NP, Collins DJ, et al. Demonstration of the reproducibility of free-breathing diffusion-weighted MRI and dynamic contrast enhanced MRI in children with solid tumours: A pilot study. Eur Radiol. 2015; 25(9): 2641–2650.
- 10Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group. J Clin Oncol. 2010; 28(11): 1963–1972.
- 11Warren KE, Poussaint TY, Vezina G, et al. Challenges with defining response to antitumor agents in pediatric neuro-oncology: A report from the response assessment in pediatric neuro-oncology (RAPNO) working group. Pediatr Blood Cancer. 2013; 60(9): 1397–1401.
- 12Carceller F, Bautista FJ, Fowkes LA, et al. Response assessment in paediatric Phase I trials according to RECIST guidelines: survival outcomes, patterns of progression and relevance of changes in tumour measurements. Pediatr Blood Cancer. 2016; 63(8): 1400–1406.
- 13Song YS, Choi SH, Park C-K, et al. True progression versus pseudoprogression in the treatment of glioblastomas: A comparison study of normalized cerebral blood volume and apparent diffusion coefficient by histogram analysis. Korean J Radiol. 14(4): 662–672.
- 14Chu HH, Choi SH, Ryoo I, et al. Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: Comparison study of standard and high-b-value diffusion-weighted imaging. Radiology. 2013; 269(3): 831–840.
- 15Jerome NP, Miyazaki K, Collins DJ, et al. Repeatability of derived parameters from histograms following non-Gaussian diffusion modelling of diffusion-weighted imaging in a paediatric oncological cohort. Eur Radiol. 2016; Epub ahead of print.
- 16Choi HS, Kim AH, Ahn SS, Shin N, Kim J, Lee S-K. Glioma grading capability: Comparisons among parameters from dynamic contrast-enhanced MRI and ADC value on DWI. Korean J Radiol. 2013; 14(3): 487–492.
- 17Mills SJ, Patankar TA, Haroon HA, Balériaux D, Swindell R, Jackson A. Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? AJNR Am J Neuroradiol. 2006; 27(4): 853–858.
- 18Lober RM, Cho Y-J, Tang Y, et al. Diffusion-weighted MRI derived apparent diffusion coefficient identifies prognostically distinct subgroups of pediatric diffuse intrinsic pontine glioma. J Neurooncol. 2014; 117(1): 175–182.
